Project Description

Paul Cislo is Director of Statistics at Pfizer. He co-leads work package 5. Paul earned his PhD in Biostatistics from Yale University and obtained18 year of pharmaceutical experience.  Nine of those years in the pharmaceutical industry, he has providing reimbursement and health economic and outcomes research (HEOR) strategy support for oncology products; which included strategy and statistical analysis planning for clinical trial-based patient reported outcomes (PRO) for products to treat breast cancer, lymphoma, prostate cancer, bladder cancer, kidney cancer, and lung cancer.  For the other nine years in industry, he has provided statistical support for all aspects of outcomes research, including patient reported outcomes across a wide range of therapeutic areas. He is currently co-leading work package 5 (Independent validation and feasibility) with Dr. Martin Taphoorn and contributing to work packages 2 (Methodological work for cancer RCTs) and 7 (Develop international recommendations for analysis and interpretation of PRO results) for this SISAQOL initiative.